RxDoctor Payments DataLook up a doctor →

Diane Burdsal

Nurse Practitioner · Charleston, SCNPI 1417421470

Payments from drug & device makers

$9,657in general payments, 2019–2025

Across 419 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1K
  • Novartis$485
  • Regeneron Healthcare Solutions, Inc.$475
  • AstraZeneca$449
  • Pfizer$413
  • Genentech USA, Inc.$403
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$9,641100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck43$1,072
Novartis22$485
Regeneron Healthcare Solutions, Inc.23$475
AstraZeneca(2 entities)22$449
Pfizer20$413
Genentech USA, Inc.18$403
Gilead(2 entities)10$372
E.r. Squibb & Sons, L.L.C.19$364
Bristol Myers Squibb17$356
Bayer14$320
Incyte Corporation12$286
Takeda Pharmaceuticals U.S.A., Inc.12$280
Lilly USA, LLC11$264
Sobi, Inc10$221
Daiichi Sankyo Inc.8$185
GSK9$178
Seagen Inc.8$167
AbbVie8$158
Beone Medicines USA, Inc.5$157
Ipsen Biopharmaceuticals, Inc7$155
Taiho Oncology, Inc.6$145
Sanofi4$132
Johnson & Johnson6$130
Stemline Therapeutics Inc.4$128
Pharmaessentia USA Corporation5$125
AVEO Pharmaceuticals, Inc.4$124
Servier Pharmaceuticals LLC5$116
Novocure Inc.3$113
Adaptive Biotechnologies Corporation5$112
ADC Therapeutics America, Inc.5$110
Azurity Pharmaceuticals, Inc.4$105
Jazz Pharmaceuticals Inc.4$96
Alnylam Pharmaceuticals Inc.4$87
Astellas Pharma US Inc4$84
Tersera Therapeutics LLC3$82
Amgen4$79
Karyopharm Therapeutics Inc.4$78
Puma Biotechnology, Inc.4$78
Genmab U.S., Inc.3$76
Acrotech Biopharma Inc.3$69
Beigene USA, Inc.3$69
Morphosys, US Inc.4$65
Pharmacosmos Therapeutics Inc.3$64
Legend Biotech USA Inc.2$58
Deciphera Pharmaceuticals Inc.2$56
Geron Corporation2$53
Eisai Inc.2$45
G1 Therapeutics, Inc.2$45
Mirati Therapeutics, Inc.2$40
Iovance Biotherapeutics, Inc.1$36
Immunocore Limited2$36
Tempus AI, Inc1$35
Shield Therapeutics Inc2$31
Sumitomo Pharma America, Inc.1$29
Rigel Pharmaceuticals, Inc.1$28
Pharmaand GmbH1$23
Tolmar, Inc.1$23
Dendreon Pharmaceuticals LLC1$22
EMD Serono, Inc.1$19
Kyowa Kirin, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,657 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$92,897
Medicare patients
581
Services billed
1,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide101$1,208,980
RevlimidLenalidomide46$821,740
ErleadaApalutamide27$452,646
PomalystPomalidomide19$421,564
VerzenioAbemaciclib27$412,586
CabometyxCabozantinib S-Malate13$335,061
XtandiEnzalutamide23$325,300
CalquenceAcalabrutinib Maleate13$211,221
KisqaliRibociclib Succinate16$180,755
EliquisApixaban72$68,886
OrgovyxRelugolix17$42,496
Abiraterone Acetate15$22,695
XareltoRivaroxaban21$17,045
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,440
MyrbetriqMirabegron11$6,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$320$1,208,980101 claims
Bristol Myers SquibbRevlimid$356$821,74046 claims
Johnson & JohnsonErleada, Xarelto$130$469,69148 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$364$421,56419 claims
Lilly USA, LLCVerzenio$264$412,58627 claims
Astellas Pharma US IncXtandi, Myrbetriq$84$331,82434 claims
AstraZenecaCalquence$449$211,22113 claims
NovartisKisqali$485$180,75516 claims
PfizerEliquis$413$68,88672 claims
Sumitomo Pharma America, Inc.Orgovyx$29$42,49617 claims
GSKTrelegy Ellipta$178$12,44020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →